1460885621-e4f54c1c-1b15-4147-8b11-a35219d59a45

1. An animation rendering system, comprising:
a high-level animation subsystem that handles interaction functions for the system;
a low-level animation subsystem that handles display functions for the system;
at least one high-level clock that is referenced by high-level animation operations;
at least one low-level clock that is referenced by low-level animation operations;
a communications channel for sending messages between the high-level animation subsystem and the low-level animation subsystem according to a communications protocol;
wherein the communication protocol further comprises at least one message sent from the low-level animation subsystem to the high-level animation subsystem to handle synchronization between the high-level animation subsystem and the low-level animation subsystem, the one message comprising a \u201csynchronize with media slip\u201d message tat identifies a target clock associated with an animation and an amount that the target clock must slip to synchronize the high-level animation subsystem with the animation being run by the low-level animation subsystem; and
wherein the communications protocol includes information provided to the low-level animation subsystem by the high-level animation subsystem that designates an animation and specifies how the animation is to change over a specified period of time, thereby ensuring that the low-level animation system has information to process several frames of the animation.
2. The animation rendering system as recited in claim 1, wherein the communications between the high-level animation subsystem and the low-level animation subsystem are asynchronous.
3. The animation rendering system as recited in claim 1, wherein:
the low-level animation subsystem renders animations at a constant display frame refresh rate; and
the high-level animation subsystem handles interactions at a variable rate that is slower than the constant display frame refresh rate.
4. The animation rendering system as recited in claim 1, wherein:
the high-level animation subsystem farther comprises a high-level timing engine;
the low-level animation subsystem further comprises a low-level timing engine; and
the communication protocol further comprises the following parameterized messages that are sent from the high-level timing engine to the low-level timing engine:
a create clock message with initial clock properties parameter;
an update properties message with a target clock parameter and an updated properties parameter;
an add interval message with a target clock parameter and an interval properties parameter;
a reset synchronization slip message with a target clock parameter;
a remove all intervals message with a target clock parameter; and
a delete clock message with a target clock to delete parameter.
5. The animation rendering system as recited in claim 1, wherein:
the high-level animation subsystem further comprises a high-level animation objects database;
the low-level animation subsystem further comprises a low-level animation objects database; and
the communication protocol further comprises the following parameterized messages that are sent from the high-level animation objects database to the low-level animation objects database:
a create animation message with an output value type parameter, an animation function parameter and a controlling clock parameter;
an update animation message with a target animation parameter and an updated properties parameter;
a create animation collection message with a list of animations parameter;
an add animation to collection message with a target animation collection parameter and an animation to add parameter;
a remove animation to collection message with a target animation collection parameter and an animation to remove parameter;
a create static value message with a value type parameter and an initial value parameter; and
an update static value parameter with a target static value object parameter and a new value parameter.
6. A method for processing an animation application, comprising:
receiving animation data from the animation application into a high-level animation subsystem;
transmitting animation information from the high-level animation subsystem to a low-level animation subsystem according to a communication protocol over a communications channel so that the low-level animation subsystem can display an animation associated with the animation data;
wherein the communication protocol provides for designating an animation and for instructions regarding how the animation should change over a particular time period so that the low-level animation subsystem can process several frames of the animation at a constant display frame refresh rate while the high-level animation subsystem executes at a variable refresh rate, and
wherein the communication protocol includes the following messages that are sent from a high-level animation subsystem timing element to a low-level animation subsystem timing element:
a message to create a clock;
a message to update clock properties;
a message to add an interval to a clock;
a message to remove all intervals for a clock; and
a message to delete a clock.
7. The method as recited in claim 6, wherein the communication protocol further includes the following messages that are sent from a high-level animation subsystem timing element to a low-level animation subsystem timing element: a message to reset a synchronization slip value in the low-level animation subsystem.
8. The method as recited in claim 6, wherein the communication protocol includes the following messages that are sent from a high-level animation subsystem animation object element to a low-level animation subsystem animation object element:
a message to create an animation;
a message to update an animation;
a message to create an animation collection;
a message to add an animation to an animation collection; and
a message to remove an animation from an animation collection.
9. The method as recited in claim 6, wherein the communication protocol includes the following messages that arc sent from a high-level animation subsystem animation object element to a low-level animation subsystem animation object element:
a message to create a static display value; and
a message to update a static display value.
10. A system, comprising:
a high-level animation subsystem configured to receive animation information from an application;
a low-level animation subsystem configured to render one or more animations according to the animation information;
a low-level timing engine configured to monitor one or more low-level clocks in the low-level animation subsystem and to synchronize the low-level clocks with one or more high-level clocks;
a high-level timing engine configured to monitor one or more high-level clocks in the high-level animation subsystem according to one or more high-level animation objects and to transmit animation messages to the low-level timing engine, the animation messages conforming to a communication protocol;
wherein the low-level timing engine is configured to send a synchronization message to the high-level timing engine according to the communication protocol that identifies a high-level clock and measure of how much the high-level clock should be altered to synchronize the high-level clock with a low-level clock; and
wherein the animation messages that are transmitted from the high-level timing engine to the low-level timing engine designate one or more animation objects and how the animation objects are to change over a specified period of time.
11. The system as recited in claim 10, wherein the low-level timing engine synchronizes a low-level clock with a high-level clock by sending a \u201csynchronize with media slip\u201d message that identifies the high-level clock and an amount by which the high-level clock must slip to maintain synchronization with a low-level clock that corresponds to the high-level clock.
12. The system as recited in claim 10, wherein the communication protocol further comprises the following messages:
a create clock message that identifies clock properties;
an update properties message that identifies updated clock properties;
an add interval mess age that adds a timing interval to clock properties;
a remove intervals message that removes timing intervals from clock properties; and
a delete clock message that deletes a clock.
13. The system as recited in claim 10, wherein the communication protocol further comprises the following messages:
a create animation message that creates an animation;
an update animation message that updates an existing animation;
a create animation collection tat identifies multiple animations to be grouped;
an add animation to collection message that identifies an animation to add to an identified animation collection; and
a remove animation to collection message that identifies an animation to remove from an identified animation collection.
14. The system as recited in claim 10, wherein the communication protocol further comprises the following messages:
a create static value message tat identifies a value type and an initial value to display; and
an update static value message that identifies a static value to update and a new value for the static value.
15. The system as recited in claim 10, further comprising:
at least one low-level animation object;
at least one high-level animation object configured to communicate with the low-level animation objects through communication protocol messages to create and update the low-level animation objects to reflect the high-level animation objects.
16. A high-level animation subsystem in an animation rendering system, comprising:
one or more high-level clocks;
a high-level timing engine configured to track the one or more high-level clocks;
one or more animation objects that identify at least a portion of an animation;
means for transmitting animation data to a low-level animation subsystem according to messages included in a communication protocol; and
wherein the communication protocol messages transmitted to the low-level animation subsystem identifies at least one of the animation objects in the low-level animation subsystem and provides data regarding bow the identified animation objects are to change over a specified period of time, and
wherein the communication protocol further comprises the following messages:
a create animation message that describes an animation to create; and
an update animation message that identifies an animation to update and updated properties.
17. The high-level animation subsystem recited in claim 16, wherein the communication protocol further comprises the following messages;
a create clock message that identifies initial clock properties;
an update properties message that identifies updated clock properties;
an add interval message that identifies an interval to be added to a clock;
a remove all intervals message that identifies a clock from which all intervals are to be removed; and
a delete clock message that identifies a clock to be deleted.
18. The high-level animation subsystem recited in claim 16, wherein the communication protocol further comprises the following messages:
a create animation collection message that identifies multiple animations that are to be grouped as one animation collection;
an add animation to collection message that identifies an animation to be added to an identified animation collection; and
a remove animation from collection message that identifies an animation to be removed from an identified animation collection.
19. The high-level animation subsystem recited in claim 16, wherein the communication protocol further comprises the following messages:
a create static value message that identifies a value type and an initial value to render; and
an update static value message that identifies a static value to update and a new value for the static value.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula I:
or stereoisomers or pharmaceutically acceptable salts thereof, wherein:
M is absent or selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
Q is selected from CH2, CHR5, CHR13, CR13R13, and CR5R13;
J, K, and L are independently selected from CH2, CHR5, CHR6, CR6R6 and CR5R6;
with the provisos:
1) at least one of M, J, K, L, or Q contains an R5; and
2) when M is absent, J is selected from CH2, CHR5, CHR13, and CR5R13;
E is \u2014(CR7R8)\u2014(CR9R10)v\u2014;
Y is selected from:
X is selected from NR14, O, and S;
Z is selected from C(O)R3, S(O)2R3, C(O)OR3, C(O)NR2R3, C(\u2550NR1)NR2R3, C(\u2550CHCN)NR2R3, C(\u2550CHNO2)NR2R3, C(\u2550C(CN)2)NR2R3, and (CR\u2032R\u2032)t-phenyl substituted with 0-5 R15;
R\u2032, at each occurrence, is selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, and (CH2)rphenyl substituted with R15e;
R1 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, OH, CN, and (CH2)wphenyl;
R2 is selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, and a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R2a;
R2a, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR2bR2b, (CH2)rOH, (CH2)rOR2c, (CH2)rSH, (CH2)rSR2c, (CH2)rC(O)R2b, (CH2)rC(O)NR2bR2b, (CH2)rNR2bC(O)R2b, (CH2)rC(O)OR2b, (CH2)rOC(O)R2c, (CH2)rCH(\u2550NR2b)NR2bR2b, (CH2)rNHC(\u2550NR2b)NR2bR2b, (CH2)rS(O)pR2c, (CH2)rS(O)2NR2bR2b, (CH2)rNR2bS(O)2R2c, and (CH2)rphenyl;
R2b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl;
R2c, at each occurrence, is selected from C1-5 alkyl, C3-6 cycloalkyl, and phenyl;
R3 is selected from a CR3\u2032R3\u2033R3\u2033, (CR3\u2032R3\u2033)r\u2014C3-10 carbocyclic residue substituted with 0-5 R15 and a (CR3\u2032R3\u2033)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R3\u2032 and R3\u2033, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, and phenyl;
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)qC(O)R4b, (CH2)qC(O)NR4aR4a\u2032, (CH2)qC(O)OR4b, and a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-3 R4c;
R4a and R4a\u2032, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, and phenyl;
R4b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, (CH2)rC3-6 cycloalkyl, C2-8 alkynyl, and phenyl;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, (CH2)rNR4aR4a\u2032, and (CH2)rphenyl;
R5 is selected from a (CR5\u2032R5\u2033)t\u2014C3-10 carbocyclic residue substituted with 0-5 R16 and a (CR5\u2032R5\u2033)t-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16;
R5\u2032 and R5\u2033, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, and phenyl;
R6, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CF2)rCF3, CN, (CH2)rNR6aR6a\u2032, (CH2)rOH, (CH2)rOR6b, (CH2)rSH, (CH2)rSR6b, (CH2)rC(O)OH, (CH2)rC(O)R6b, (CH2)rC(O)NR6aR6a\u2032, (CH2)rNR6dC(O)R6a, (CH2)rC(O)OR6b, (CH2)rOC(O)R6b, (CH2)rS(O)pR6b, (CH2)rS(O)2NR6aR6a\u2032, (CH2)rNR6dS(O)2R6b, and (CH2)tphenyl substituted with 0-3 R6c;
R6a and R6a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, and (CH2)rNR6dR6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7 is selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qOR7d, (CH2)qSR7d, (CH2)qNR7aR7a\u2032, (CH2)rC(O)OH, (CH2)rC(O)R7b, (CH2)rC(O)NR7aR7a\u2032, (CH2)qNR7aC(O)R7a, (CH2)rC(O)OR7b, (CH2)qOC(O)R7b, (CH2)qS(O)pR7b, (CH2)qS(O)2NR7aR7a\u2032, (CH2)qNR7aS(O)2R7b, C1-6 haloalkyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-3 R7c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R7c;
R7aand R7a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R7e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-6 carbocyclic residue substituted with 0-2 R7e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R7e;
R7c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR7fR7f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)R7b, (CH2)rC(O)NR7fR7f, (CH2)rNR7fC(O)R7a, (CH2)rC(O)OC1-4 alkyl, (CH2)rOC(O)R7b, (CH2)rC(\u2550NR7f)NR7fR7f, (CH2)rS(O)pR7b, (CH2)rNHC(\u2550NR7f)NR7fR7f, (CH2)rS(O)2NR7fR7f, (CH2)rNR7fS(O)2R7b, and (CH2)rphenyl substituted with 0-3 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R7e, alkenyl, alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 R7c;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR7fR7f, and (CH2)rphenyl;
R7f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R8 is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 R8a;
R8a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR7fR7f, and (CH2)rphenyl;
alternatively, R7 and R8 join to form C3-7 cycloalkyl, or \u2550NR8b;
R8b is selected from H, C1-6 alkyl, C3-6 cycloalkyl, OH, CN, and (CH2)r-phenyl;
R9 is independently selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)rOH, (CH2)rSH, (CH2)rOR9d, (CH2)rSR9d, (CH2)rNR9aR9a\u2032, (CH2)rC(O)OH, (CH2)rC(O)R9b, (CH2)rC(O)NR9aR9a\u2032, (CH2)rNR9aC(O)R9a, (CH2)rNR9aC(O)H, (CH2)rC(O)OR9b, (CH2)rOC(O)R9b, (CH2)rS(O)pR9b, (CH2)rS(O)2NR9aR9a\u2032, (CH2)rNR9aS(O)2R9b, C1-6 haloalkyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R9c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9c;
R9\u2032 is independently selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)rOH, (CH2)rSH, (CH2)rOR9d, (CH2)rSR9d, (CH2)rNR9aR9a\u2032, (CH2)rC(O)OH, (CH2)rC(O)R9b, (CH2)rC(O)NR9aR9a\u2032, (CH2)rNR9aC(O)R9a, (CH2)rNR9aC(O)H, (CH2)rC(O)OR9b, (CH2)rOC(O)R9b, (CH2)rS(O)pR9b, (CH2)rS(O)2NR9aR9a\u2032, (CH2)rNR9aS(O)2R9b, C1-6 haloalkyl, (CH2)r\u2014C3-6 cycloalkyl, (CH2)q-phenyl substituted with 0-5 R9c, and a (CH2)q-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9c;
R9a and R9a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R9e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-6 carbocyclic residue substituted with 0-2 R9e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R9e;
R9c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR9fR9f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)R9b, (CH2)rC(O)NR9fR9f, (CH2)rNR9fC(O)R9a, (CH2)rC(O)OC1-4 alkyl, (CH2)rOC(O)R9b, (CH2)rC(\u2550NR9f)NR9fR9f, (CH2)rS(O)pR9b, (CH2)rNHC(\u2550NR9f)NR9fR9f, (CH2)rS(O)2NR9fR9f, (CH2)rNR9fS(O)2R9b, and (CH2)rphenyl substituted with 0-3 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R9c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R9c;
R9e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
R9f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R10 is independently selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, F, Cl, Br, I, NO2, CN, (CH2)rOH, (CH2)rOR10d, (CH2)rSR10d, (CH2)rNR10aR10a\u2032, (CH2)rC(O)OH, (CH2)rC(O)R10b, (CH2)rC(O)NR10aR10a\u2032, (CH2)rNR10aC(O)R10a, (CH2)rNR10aC(O)H, (CH2)rC(O)OR10b, (CH2)rOC(O)R10b, (CH2)rS(O)pR10b, (CH2)rS(O)2NR10aR10a\u2032, (CH2)rNR10aS(O)2R10b, C1-6 haloalkyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R10c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10c;
R10a and R10a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R10e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10e;
R10b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-6 carbocyclic residue substituted with 0-2 R10e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R10e;
R10c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR10fR10f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)R10b, (CH2)rC(O)NR10fR10f, (CH2)rNR10fC(O)R10a, (CH2)rC(O)OC1-4 alkyl, (CH2)rOC(O)R10b, (CH2)rC(\u2550NR10f)NR10fR10f, (CH2)rS(O)pR10b, (CH2)rNHC(\u2550NR10f)NR10fR10f, (CH2)rS(O)2NR10fR10f, (CH2)rNR10fS(O)2R10b, and (CH2)rphenyl substituted with 0-3 R10e;
R10d, at each occurrence, is selected from C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, a C3-10 carbocyclic residue substituted with 0-3 R10c, and a 5-6 membered heterocyclic system containing 1-4 heteroatoms selected from the group consisting of N, O, and S substituted with 0-3 R10c;
R10e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR10fR10f, and (CH2)rphenyl;
R10f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
with the proviso that when R10 is \u2014OH, R9 is not halogen, cyano, or bonded to the carbon to which it is attached through a heteroatom;
alternatively, R9 and R10 join to form C3-7 cycloalkyl;
R11 is selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qOR11d, (CH2)qSR11d, (CH2)qNR11aR11a\u2032, (CH2)rC(O)OH, (CH2)rC(O)R11b, (CH2)rC(O)NR11aR11a\u2032, (CH2)qNR11aC(O)R11a, (CH2)rC(O)OR11b, (CH2)qOC(O)R11b, (CH2)qS(O)pR11b, (CH2)qS(O)2NR11aR11a\u2032, (CH2)qNR11aS(O)2R11b, C1-6 haloalkyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R11c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11c;
R11\u2032 is selected from H, C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)qOH, (CH2)qSH, (CH2)qOR11d, (CH2)qSR11d, (CH2)qNR11aR11a\u2032, (CH2)rC(O)OH, (CH2)rC(O)R11b, (CH2)rC(O)NR11aR11a\u2032, (CH2)qNR11aC(O)R11a, (CH2)rC(O)OR11b, (CH2)qOC(O)R11b, (CH2)qS(O)pR11b, (CH2)qS(O)2NR11aR11a\u2032, (CH2)qNR11aS(O)2R11b, C1-6 haloalkyl, a (CH2)r\u2014C3-6 cycloalkyl, (CH2)q-phenyl substituted with 0-5 R11c, and a (CH2)q-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11c;
R11a and R11a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R11e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-6 carbocyclic residue substituted with 0-2 R11e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R11e;
R11c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR11fR11f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rSC1-4 alkyl, (CH2)rC(O)OH, (CH2)rC(O)R11b, (CH2)rC(O)NR11fR11f, (CH2)rNR11fC(O)R11a, (CH2)rC(O)OC1-4 alkyl, (CH2)rOC(O)R11b, (CH2)rC(\u2550NR11f)NR11fR11f, (CH2)rNHC(\u2550NR11f)NR11fR11f, (CH2)rS(O)pR11b, (CH2)rS(O)2NR11fR11f, (CH2)rNR11fS(O)2R11b, and (CH2)rphenyl substituted with 0-3 R11e;
R11d, at each occurrence, is selected from C1-6 alkyl substituted with 0-3 R11e, C2-6 alkenyl, C2-6 alkynyl, and a C3-10 carbocyclic residue substituted with 0-3 R11c;
R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR11fR11f, and (CH2)rphenyl;
R11f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R12 is selected from H, C1-6 alkyl, (CH2)qOH, (CH2)rC3-6 cycloalkyl, and (CH2)tphenyl substituted with 0-3 R12a;
R12a, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
R13, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, (CF2)wCF3, (CH2)qNR13aR13a\u2032, (CH2)qOH, (CH2)qOR13b, (CH2)qSH, (CH2)qSR13b, (CH2)wC(O)OH, (CH2)wC(O)R13b, (CH2)wC(O)NR13aR13a\u2032, (CH2)qNR13dC(O)R13a, (CH2)wC(O)OR13b, (CH2)qOC(O)R13b, (CH2)wS(O)pR13b, (CH2)wS(O)2NR13aR13a\u2032, (CH2)qNR13dS(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13aand R13a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, and (CH2)rNR13dR13d;
R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R14 is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, C(O)NR14aR14a\u2032, C(O)R14b, C(O)OC1-4 alkyl, (CH2)rS(O)pR14b, (CH2)rphenyl substituted with 0-3 R14c;
R14a and R14a\u2032, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R14c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14c;
R14b, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R14c, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R14c; and
R14c, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, (CH2)wphenyl;
R15, at each occurrence, is selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR\u2032)rNR15aR15a\u2032, (CHR\u2032)rOH, (CHR\u2032)rO(CHR\u2032)rR15d, (CHR\u2032)rSH, (CHR\u2032)rC(O)H, (CHR\u2032)rS(CHR\u2032)rR15d, (CHR\u2032)rC(O)OH, (CHR\u2032)rC(O)(CHR\u2032)rR15b, (CHR\u2032)rC(O)NR15aR15a\u2032, (CHR\u2032)rNR15fC(O)(CHR\u2032)rR15b, (CHR\u2032)rC(O)O(CHR\u2032)rR15d, (CHR\u2032)rOC(O)(CHR\u2032)rR15b, (CHR\u2032)rC(\u2550NR15f)NR15aR15a\u2032, (CHR\u2032)rNHC(\u2550NR15f)NR15fR15f, (CHR\u2032)rS(O)p(CHR\u2032)rR15b, (CHR\u2032)rS(O)2NR15aR15a\u2032, (CHR\u2032)rNR15fS(O)2(CHR\u2032)rR15b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R\u2032, C2-8 alkynyl substituted with 0-3 R\u2032, (CHR\u2032)rphenyl substituted with 0-3 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15a and R15a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R15e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-6 carbocyclic residue substituted with 0-3 R15e, and (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R15e, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-3 R15e, and a (CH2)r5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15e;
R15e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR15fR15f, and (CH2)rphenyl;
R15f, at each occurrence, is selected from H, C1-5 alkyl, C3-6 cycloalkyl, and phenyl;
R16, at each occurrence, is selected from C1-8 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, NO2, CN, (CHR\u2032)rNR16aR16a\u2032, (CHR\u2032)rOH, (CHR\u2032)rO(CHR\u2032)rR16d, (CHR\u2032)rSH, (CHR\u2032)rC(O)H, (CHR\u2032)rS(CHR\u2032)rR16d, (CHR\u2032)rC(O)OH, (CHR\u2032)rC(O)(CHR\u2032)rR16b, (CHR\u2032)rC(O)NR16aR16a\u2032, (CHR\u2032)rNR16fC(O)(CHR\u2032)rR16b, (CHR\u2032)rC(O)O(CHR\u2032)rR16d, (CHR\u2032)rOC(O)(CHR\u2032)rR16b, (CHR\u2032)rC(\u2550NR16f)NR16aR16a\u2032, (CHR\u2032)rNHC(\u2550NR16f)NR16fR16f, (CHR\u2032)rS(O)p(CHR\u2032)rR16b, (CHR\u2032)rS(O)2NR16aR16a\u2032, (CHR\u2032)rNR16fS(O)2(CHR\u2032)rR16b, C1-6 haloalkyl, C2-8 alkenyl substituted with 0-3 R\u2032, C2-8 alkynyl substituted with 0-3 R\u2032, and (CHR\u2032)rphenyl substituted with 0-3 R16e;
R16a and R16a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-5 R16e, and a (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, a (CH2)rC3-6 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R16e;
R16d, at each occurrence, is selected from C2-8 alkenyl, C2-8 alkynyl, C1-6 alkyl substituted with 0-3 R16e, a (CH2)r\u2014C3-10 carbocyclic residue substituted with 0-3 R16e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R16e;
R16e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR16fR16f, and (CH2)rphenyl;
R16f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl, and phenyl;
v is selected from 0, 1, and 2;
t is selected from 1 and 2;
w is selected from 0 and 1;
r is selected from 0, 1, 2, 3, 4, and 5;
q is selected from 1, 2, 3, 4, and 5; and
p is selected from 1, 2, and 3.
2. The compound according to claim 1, wherein:
R4 is absent, taken with the nitrogen to which it is attached to form an N-oxide, or selected from C1-8 alkyl, (CH2)rC3-6 cycloalkyl, and (CH2)r-phenyl substituted with 0-3 R4c;
R4c, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, (CH2)rNR4aR4a\u2032, and (CH2)rphenyl;
R2 is selected from H and C1-4 alkyl;
R6, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CF2)rCF3, CN, (CH2)rOH, (CH2)rOR6b, (CH2)rC(O)R6b, (CH2)rC(O)NR6aR6a\u2032, (CH2)rNR6dC(O)R6a, and (CH2)tphenyl substituted with 0-3 R6c;
R6a and R6a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R6c;
R6c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, (CH2)rSC1-5 alkyl, and (CH2)rNR6dR6d;
R6d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R7, is selected from H, C1-3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qOR7d, (CH2)qNR7aR7a\u2032, (CH2)rC(O)R7b, (CH2)rC(O)NR7aR7a\u2032, (CH2)qNR7aC(O)R7a, C1-6 haloalkyl, (CH2)rphenyl with 0-2 R7c;
R7aand R7a\u2032, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, a (CH2)rphenyl substituted with 0-3 R7e;
R7b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 R7e;
R7c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR7fR7f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rC(O)R7b, (CH2)rC(O)NR7fR7f, (CH2)rNR7fC(O)R7a, (CH2)rS(O)pR7b, (CH2)rS(O)2NR7fR7f, (CH2)rNR7fS(O)2R7b, and (CH2)rphenyl substituted with 0-2 R7e;
R7d, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 R7e;
R7e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR7fR7f, and (CH2)rphenyl;
R7f, at each occurrence, is selected from H, C1-5 alkyl, and C3-6 cycloalkyl;
R8 is H or joins with R7 to form \u2550NR8b;
R9, is selected from H, C-1-3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)rOH, (CH2)rOR9d, (CH2)rNR9aR9a\u2032, (CH2)rC(O)R9b, (CH2)rC(O)NR9aR9a\u2032, (CH2)rNR9aC(O)R9a, C1-6 haloalkyl, (CH2)rphenyl with 0-2 R9c, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R9\u2032, is selected from H, C1-3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)rOH, (CH2)rOR9d, (CH2)rNR9aR9a\u2032, (CH2)rC(O)R9b, (CH2)rC(O)NR9aR9a\u2032, (CH2)rNR9aC(O)R9a, C1-6 haloalkyl, (CH2)rphenyl with 0-2 R9c, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R9a and R9a\u2032, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, a (CH2)rphenyl substituted with 0-3 R9e;
R9b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 R9e;
R9c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR9fR9f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rC(O)R9b, (CH2)rC(O)NR9fR9f, (CH2)rNR9fC(O)R9a, (CH2)rS(O)pR9b, (CH2)rS(O)2NR9fR9f, (CH2)rNR9fS(O)2R9b, and (CH2)rphenyl substituted with 0-2 R9e;
R9d, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 R9e;
R9e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR9fR9f, and (CH2)rphenyl;
R9f, at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;
R10 is H;
R11, is selected from H, C1-3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qOR11d, (CH2)qNR11aR11a\u2032, (CH2)rC(O)R11b, (CH2)rC(O)NR11aR11a\u2032, (CH2)qNR11aC(O)R11a, C1-6 haloalkyl, (CH2)rphenyl with 0-2 R11c, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R11\u2032, is selected from H, C1-3 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)qOH, (CH2)qOR11d, (CH2)qNR11aR11a\u2032, (CH2)rC(O)R11b, (CH2)rC(O)NR11aR11a\u2032, (CH2)qNR11aC(O)R11a, C1-6 haloalkyl, (CH2)rphenyl with 0-2 R11c, (CH2)r-5-10 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-3 R15;
R11a and R11a\u2032, at each occurrence, are selected from H, C1-6 alkyl, (CH2)rC3-6 cycloalkyl, a (CH2)rphenyl substituted with 0-3 R11e;
R11b, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 R11e;
R11c, at each occurrence, is selected from C1-4 alkyl, C2-8 alkenyl, C2-8 alkynyl, (CH2)rC3-6 cycloalkyl, Cl, Br, I, F, (CF2)rCF3, NO2, CN, (CH2)rNR11fR11f, (CH2)rOH, (CH2)rOC1-4 alkyl, (CH2)rC(O)R11b, (CH2)rC(O)NR11fR11f, (CH2)rNR11fC(O)R11a, (CH2)rS(O)pR11b, (CH2)rS(O)2NR11fR11f, (CH2)rNR11fS(O)2R11b, and (CH2)rphenyl substituted with 0-2 R11e;
R11d, at each occurrence, is selected from C1-6 alkyl, (CH2)rC3-6 cycloalkyl, (CH2)rphenyl substituted with 0-3 R11e;
R11e, at each occurrence, is selected from C1-6 alkyl, C2-8 alkenyl, C2-8 alkynyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, OH, SH, (CH2)rSC1-5 alkyl, (CH2)rNR11fR11f, and (CH2)rphenyl;
R11f, at each occurrence, is selected from H, C1-5 alkyl and C3-6 cycloalkyl;
R12 is H;
R13, at each occurrence, is selected from C1-4 alkyl, C3-6 cycloalkyl, (CH2)NR13aR13a\u2032, (CH2)OH, (CH2)OR13b, (CH2)wC(O)R13b, (CH2)wC(O)NR13aR13a\u2032, (CH2)NR13dC(O)R13a, (CH2)wS(O)2NR13aR13a\u2032, (CH2)NR13dS(O)2R13b, and (CH2)w-phenyl substituted with 0-3 R13c;
R13a and R13a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and phenyl substituted with 0-3 R13c;
R13c, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, (CH2)rOC1-5 alkyl, (CH2)rOH, and (CH2)rNR13dR13d;
R13d, at each occurrence, is selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
v is selected from 1 and 2;
q is selected from 1, 2, and 3; and
r is selected from 0, 1, 2, and 3.
3. The compound according to claim 2, wherein:
R3 is selected from a (CR3\u2032H)r-carbocyclic residue substituted with 0-5 R15, wherein the carbocyclic residue is selected from phenyl, C3-6 cycloalkyl, naphthyl, and adamantyl; and a (CR3\u2032H)r-heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl; and
R5 is selected from (CR5\u2032H)t-phenyl substituted with 0-5 R16; and a (CR5\u2032H)t-heterocyclic system substituted with 0-3 R16, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
4. The compound according to claim 3, wherein:
R4 is absent; and
R9, R9\u2032, R10, R11, R11\u2032, R12, and R13 are H.
5. The compound according to claim 4, wherein the
R16, at each occurrence, is selected from C1-8 alkyl, (CH2)rC3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)rNR16aR16a\u2032, NO2, CN, OH, (CH2)rOR16d, (CH2)rC(O)R16b, (CH2)rC(O)NR16aR16a\u2032, (CH2)rNR16fC(O)R16b, (CH2)rS(O)pR16b, (CH2)rS(O)2NR16aR16a\u2032, (CH2)rNR16fS(O)2R16b, and (CH2)rphenyl substituted with 0-3 R16e;
R16aand R16a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R16e;
R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R16e;
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R16e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and
R16f, at each occurrence, is selected from H, and C1-5 alkyl.
6. The compound according to claim 5, wherein R5 is CH2-phenyl substituted with 0-3 R16.
7. The compound according to claim 6, wherein:
R3 is selected from a carbocyclic residue substituted with 0-3 R15, wherein the carbocyclic residue is selected from phenyl and C3-6 cycloalkyl; and a heterocyclic system substituted with 0-3 R15, wherein the heterocyclic system is selected from pyridinyl, thiophenyl, furanyl, indazolyl, benzothiazolyl, benzimidazolyl, benzothiophenyl, benzofuranyl, benzoxazolyl, benzisoxazolyl, quinolinyl, isoquinolinyl, imidazolyl, indolyl, isoindolyl, piperidinyl, pyrrazolyl, 1,2,4-triazolyl, 1,2,3-triazolyl, tetrazolyl, thiazolyl, oxazolyl, pyrazinyl, and pyrimidinyl.
8. The compound according to claim 7, wherein:
R15, at each occurrence, is selected from C1-8 alkyl, (CH2)rC3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)rNR15aR15a\u2032, NO2, CN, OH, (CH2)rOR15d, (CH2)rC(O)R15b, (CH2)rC(O)NR15aR15a\u2032, (CH2)rNR15fC(O)R15b, (CH2)rS(O)pR15b, (CH2)rS(O)2NR15aR15a\u2032, (CH2)rNR15fS(O)2R15b, (CH2)rphenyl substituted with 0-3 R15e, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15a and R15a\u2032, at each occurrence, are selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e;
R15d, at each occurrence, is selected from C1-6 alkyl and phenyl;
R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl; and
R15f, at each occurrence, is selected from H, and C1-5 alkyl.
9. The compound according to claim 8, wherein E is \u2014CR7R8\u2014.
10. The compound according to claim 9, wherein:
Z is selected from C(O)NR2R3, C(\u2550NR1)NR2R3, C(\u2550CHCN)NR2R3, C(\u2550CHNO2)NR2R3, and C(\u2550C(CN)2)NR2R3.
11. The compound according to claim 10, wherein:
R6 is H; and
when K is CHR5, either:
1) M is absent, or
2) Z is other than C(O)NR2R3.
12. The compound according to claim 11, wherein E is
\u2014CH2\u2014.
13. The compound according to claim 11, wherein:
Y is selected from:
14. The compound according to claim 13, wherein:
Y is selected from:
15. The compound according to claim 11, wherein:
R16, at each occurrence, is selected from C1-8 alkyl, (CH2)rC3-6 cycloalkyl, CF3, Cl, Br, I, F, (CH2)rNR16aR16a\u2032, CN, OH, OCF3, (CH2)rOR16d, (CH2)rC(O)R16b;
R16a and R16a\u2032, at each occurrence, are selected from H, C1-6 alkyl, and C3-6 cycloalkyl;
R16b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R16e;
R16d, at each occurrence, is selected from C1-6 alkyl and phenyl.
16. The compound according to claim 15, wherein R16 is selected from F, Cl, Br, OCF3, and CF3.
17. The compound according to claim 11, wherein:
R15, at each occurrence, is selected from CN,C(O)R15b, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15b, at each occurrence, is selected from H, C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e; and
R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl.
18. The compound according to claim 15, wherein:
R15, at each occurrence, is selected from CN, C(O)R15b, and a (CH2)r-5-6 membered heterocyclic system containing 1-4 heteroatoms selected from N, O, and S, substituted with 0-2 R15e;
R15b, at each occurrence, is selected from C1-6 alkyl, C3-6 cycloalkyl, and (CH2)rphenyl substituted with 0-3 R15e; and
R15e, at each occurrence, is selected from C1-6 alkyl, Cl, F, Br, I, CN, NO2, (CF2)rCF3, OH, and (CH2)rOC1-5 alkyl.
19. The compound according to claim 11, wherein:
J and Q are CH2; and
M is absent or CH2.
20. The compound according to claim 15, wherein:
E is \u2014CH2\u2014; and
Y is selected from:
21. The compound according to claim 17, wherein:
E is \u2014CH2\u2014; and
Y is selected from:
22. The compound according to claim 19, wherein:
Y is:
23. The compound according to claim 19, wherein:
Y is:
and X is selected from O and NR14.
24. The compound according to claim 22, wherein K is CH2.
25. The compound according to claim 23, wherein K is CH2.
26. The compound according to claim 1, wherein:
Z is selected from C(\u2550NR1)NR2R3 and C(\u2550C(CN)2)NR2R3.
27. The compound according to claim 2, wherein:
Z is selected from C(\u2550NR1)NR2R3 and C(\u2550C(CN)2)NR2R3.
28. The compound according to claim 4, wherein:
Z is selected from C(\u2550NR1)NR2R3 and C(\u2550C(CN)2)NR2R3.
29. The compound according to claim 7, wherein:
Z is selected from C(\u2550NR1)NR2R3 and C(\u2550C(CN)2)NR2R3.
30. The compound according to claim 13, wherein:
Z is selected from C(\u2550NR1)NR2R3 and C(\u2550C(CN)2)NR2R3.
31. The compound according to claim 22, wherein:
Z is selected from C(\u2550NCN)NR2R3 and C(\u2550C(CN)2)NR2R3.
32. The compound according to claim 23, wherein:
Z is selected from C(\u2550NCN)NR2R3 and C(\u2550C(CN)2)NR2R3.
33. The compound according to claim 24, wherein:
Z is selected from C(\u2550NCN)NHR3 and C(\u2550C(CN)2)NHR3; and R16 is selected from F, Cl, Br, OCF3, and CF3.
34. The compound according to claim 25, wherein:
Z is selected from C(\u2550NCN)NHR3 and C(\u2550C(CN)2)NHR3; and R16 is selected from F, Cl, Br, OCF3, and CF3.
35. The compound according to claim 14, wherein:
Z is selected from C(\u2550NCN)NR2R3 and C(\u2550C(CN)2)NR2R3.
36. The compound according to claim 11, wherein R3 is phenyl substituted with 0-3 R15.
37. The compound according to claim 14, wherein R3 is phenyl substituted with 0-3 R15.
38. The compound according to claim 17, wherein R3 is phenyl substituted with 0-3 R15.
39. The compound according to claim 14, wherein:
R3 is phenyl substituted with 0-3 R15;
Z is selected from C(\u2550NR1)NR2R3 and C(\u2550C(CN)2)NR2R3;
J and Q are CH2; and
M is absent or CH2.
40. The compound according to claim 1, wherein the compound of formula I is selected from:
(+\u2212)-N-phenyl-3-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-3-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(1-adamantyl)-3-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
N-phenyl-4-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
N-(3-cyanophenyl)-4-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
N-(1-adamantyl)-4-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
N-(3-methoxyphenyl)-4-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
N-(3-carboethoxyphenyl)-4-4-(phenylmethyl)-1-piperidinylmethyl-1-piperidinecarboxamide,
1-benzoyl-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-phenylacetyl-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(3,4-dimethoxybenzoyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(3,5-dichlorobenzoyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(3,5-difluorobenzoyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(3,5-dimethoxybenzoyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(3,4-methylenedioxybenzoyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(2-thiophenesulfonyl)-4-(4-(phenylmethyl)-1-piperidinylmethyl-piperidinecarboxamide,
1-(3-methoxyphenylacetyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
1-(4-methoxyphenylacetyl)-4-4-(phenylmethyl)-1-piperidinylmethylpiperidine,
(+\u2212)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(1-adamantylphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(1-adamantylphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-1-phenylsulfonyl-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-piperidinecarboxamide,
(+\u2212)-1-benzoyl-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-1-benzyloxycarbonyl-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-pyrrolidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-pyrrolidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-pyrrolidinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-pyrrolidinecarboxamide,
(+\u2212)-N-(4-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-pyrrolidinecarboxamide,
(+\u2212)-N-(1-adamantylphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-pyrrolidinecarboxamide,
(+\u2212)-N-phenyl-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-carboethoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-(1-adamantylphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1-piperidinecarboxamide,
(+\u2212)-N-phenyl-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(4-carboethoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(1-adamantylphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-(4-carboethoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-(1-adamantylphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-phenyl-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-2-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-4-morpholinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-hydroxy-1-piperidinecarboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-hydroxy-1-piperidinecarboxamide,
(+\u2212)-N-(4-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-hydroxy-1-piperidinecarboxamide,
(+\u2212)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-hydroxy-1-piperidinecarboxamide,
(+\u2212)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-hydroxy-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-hydroxy-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-phenylmethyl-1-piperidine-carboxamide,
(+\u2212)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-phenylmethyl-1-piperidine-carboxamide,
(+\u2212)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3-phenylmethyl-1-piperidine-carboxamide,
(+\u2212)-(cis)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidine-carboxamide,
(+\u2212)-(cis)-N-(3-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(cis)-N-(4-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(cis)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidine carboxamide,
(+\u2212)-(cis)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidine-carboxamide,
(+\u2212)-(cis)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(trans)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(trans)-N-(3-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(trans)-N-(4-carboethoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(trans)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(trans)-N-phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidine carboxamide,
(+\u2212)-(trans)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-(trans)-N-(3-acetylphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-2-phenylmethyl-1-piperidinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3,4-dihydro-2(1H)isoquinoline-carboxamide,
(+\u2212)-N-(phenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3,4-dihydro-2(1H)isoquinolinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3,4-dihydro-2(1H)isoquinoline-carboxamide,
(+\u2212)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1,2,3,4-tetrahydro-2-(phenylacetyl)isoquinoline,
(+\u2212)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-1,2,3,4-tetrahydro-2-(phenylmethylsulfonyl)isoquinoline,
(+\u2212)-Phenyl-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3,4-dihydro-2(1H)isoquinolinecarboxylate,
(+\u2212)-N-(4-cyanophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3,4-dihydro-2(1H)isoquinoline-carboxamide,
(+\u2212)-N-(4-fluorophenyl)-3-4-(4-fluorophenyl)methyl-1-piperidinylmethyl-3,4-dihydro-2(1H)isoquinoline-carboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-2-4-(phenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-3-4-(phenyl)methyl-1-piperidinylethyl-1,2,3,4-tetrahydro-2-(phenylsulfonyl)isoquinoline,
(+\u2212)-N-(4-fluorophenyl)-3-2-4-(phenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-N-(phenyl)-3-2-4-(phenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxamide,
(+\u2212)-3-4-(phenyl)methyl-1-piperidinylethyl-1,2,3,4-tetrahydro-2-(2-thiophenesulfonyl)isoquinoline,
(+\u2212)-3-4-(phenyl)methyl-1-piperidinylethyl-1,2,3,4-tetrahydro-2-(phenacetyl)isoquinoline,
(+\u2212)-N-(3-methoxyphenyl)-3-2-4-(phenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-N-(phenyl)-3-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-N-(3-methoxyphenyl)-3-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-N-(3-cyanophenyl)-3-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-3-4-(4-fluorophenyl)methyl-1-piperidinylethyl-1,2,3,4-tetrahydro-2-(phenylmethylsulfonyl)isoquinoline,
(+\u2212)-Phenyl-3-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate,
(+\u2212)-N-(3-carboethoxyphenyl)-3-2-4-(phenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-N-(3-carboethoxyphenyl)-3-2-4-(4-fluorophenyl)methyl-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxamide,
(+\u2212)-N-(3-cyanophenyl)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxamide,
(+\u2212)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)phenylsulfonyl isoquinoline,
(+\u2212)-N-(4-fluorophenyl)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxamide,
(+\u2212)-N-(phenyl)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxamide,
(+\u2212)-N-(3-methoxyphenyl)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-Phenyl-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxylate,
(+\u2212)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)phenacetyl isoquinoline,
(+\u2212)-N-(3-cyanophenyl)-4-2-4-(4-fluorophenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-4-2-4-(4-fluorophenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-phenylsulfonyl isoquinoline,
(+\u2212)-4-2-4-(4-fluorophenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)phenacetylisoquinoline,
(+\u2212)-4-2-4-(4-fluorophenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-phenylmethylsulfonylisoquinoline,
(+\u2212)-N-(4-carbethoxyphenyl)-4-2-4-(4-fluorophenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinoline-carboxamide,
(+\u2212)-N-(4-fluorophenyl)-4-2-4-(phenylmethyl)-1-piperidinylethyl-3,4-dihydro-2(1H)-isoquinolinecarboxamide,
(2R)-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-4-(2R)-3,3,3-trifluoro-2-methoxy-2-phenylpropanoylmorpholine,
(2R)-N-(3-acetylphenyl)-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-4-morpholinecarboxamide,
(2R)-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-N-(3-methoxyphenyl)-4-morpholinecarboxamide,
(2R)-N-(3-cyanophenyl)-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-4-morpholinecarboxamide,
(2R)-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-N-(4-fluorophenyl)-4-morpholinecarboxamide,
(2R)-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-N-phenyl-4-morpholinecarboxamide,
(2R)-N-(3-cyanophenyl)-2-{(3S)-3-(4-fluorobenzyl)piperidinylmethyl}-4-morpholinecarboxamide,
(2R)-N-(3-acetylphenyl)-2-{(3S)-3-(4-fluorobenzyl)piperidinylmethyl}-4-morpholinecarboxamide,
(2R)-N-(3-acetylphenyl)-2-{(3S)-3-(4-fluorobenzyl)piperidinylmethyl}-N-phenyl-4-morpholinecarboxamide,
3-{3-(4-fluorobenzyl)-1-pyrrolidinylmethyl}-N-phenyl-1-piperidinecarboxamide,
N-(3-cyanophenyl)-3-{3-(4-fluorobenzyl)-1-pyrrolidinylmethyl}-1-piperidinecarboxamide,
N-(3-acetylphenyl)-3-{3-(4-fluorobenzyl)-1-pyrrolidinylmethyl}-1-piperidinecarboxamide,
3-{(3S)-3-(4-fluorobenzyl)piperidinylmethyl}-N-phenyl-1-piperidinecarboxamide,
N-(3-cyanophenyl)-3-{(3S)-3-(4-fluorobenzyl)piperidinylmethyl}-1-piperidinecarboxamide,
N-(3-acetylphenyl)-3-{(3S)-3-(4-fluorobenzyl)piperidinylmethyl}-1-piperidinecarboxamide,
tert-butyl 4-(3-cyanoanilino)carbonyl-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxylate,
N-(3-cyanophenyl)-3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxamide dihydrochloride,
4-benzyl-N-(3-cyanophenyl)-3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxamide,
4-acetyl-N-(3-acetylphenyl)-3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxamide,
tert-butyl 4-(anilino)carbonyl-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piper azinecarboxylate,
tert-butyl 4-(3-methoxyanilino)carbonyl-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxylate,
tert-butyl 4-(3-acetylanilino)carbonyl-2-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxylate,
3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-N-phenyl-1-piperazinecarboxamide dihydrochloride,
3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-N-(3-methoxyphenyl)-1-piperazinecarboxamide dihydrochloride,
N-(3-acetylphenyl)-3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxamide dihydrochloride, and
4-benzyl-N-(3-cyanophenyl)-3-{4-(4-fluorobenzyl)-1-piperidinylmethyl}-1-piperazinecarboxamide.
41. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 1.
42. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound according to claim 11.
43. A method for modulation of chemokine receptor activity comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
44. The method according to claim 43, wherein R9, R9\u2032, R10, R11, R11\u2032 and R12 of the compound according to claim 1 are H.
45. The method according to claim 44, wherein modulation comprises contacting a CCR3 receptor with an effective inhibitory amount of the compound.
46. A method for treating or preventing inflammatory disorders comprising administering to a patient in need thereof a therapeutically effective amount of a compound according to claim 1.
47. The method according to claim 46, wherein R9, R9\u2032, R10, R11, R11\u2032 and R12 of the compound according to claim 1 are H.
48. The method according to claim 46, wherein the disorder is selected from asthma, allergic rhinitis, atopic dermatitis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, bullous pemphigoid, helminthic parasitic infections, allergic colitis, eczema, conjunctivitis, transplantation, familial eosinophilia, eosinophilic cellulitis, eosinophilic pneumonias, eosinophilic fasciitis, eosinophilic gastroenteritis, drug induced eosinophilia, HIV infection, cystic fibrosis, Churg-Strauss syndrome, lymphoma, Hodgkin’s disease, and colonic carcinoma.
49. The method according to claim 48, wherein the disorder is selected from asthma, allergic rhinitis, atopic dermatitis, and inflammatory bowel diseases.
50. The method according to claim 49, wherein the disorder is asthma.